secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2026-09-10T12:48:26+00:00
Accession:  0001193125-26-387351
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DISC-3405 cuts phlebotomy events 85% in PV Phase 2; hematocrit controlled <45%
------------------------------------------------------------------------------

- Mean phlebotomy events fell from 4.0 to 0.6 per 26 weeks (p<0.0001) in Cohort A (n=13).
- 61.5% of patients phlebotomy-free through 26 weeks; 77.8% during maintenance (weeks 12-32, n=9).
- Hematocrit maintained <45% through week 26 with improved symptom burden; dose-proportional PK, increased hepcidin.
- DISC-3405 well-tolerated; mild injection site reactions; adverse events consistent with underlying disease.
- Company plans RESTORE-PV update and sickle cell data by end of 2026; selcodebart FDA feedback expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/0001193125-26-387351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000119312526387351/iron-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-387351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer